BBIO Stock Forecast & Price Target

BridgeBio Pharma is supported by a rare combination of an already commercialized growth driver and multiple late-stage value catalysts, with Attruby generating $222MM in U.S. sales in 2Q26 (+23% q/q, +211% y/y) while the TTR-CM market expanded 19% q/q and 51% y/y. The bullish case is strengthened by the view that Attruby’s stabilizer-first profile, durable gross-to-net in the 30-40% range, and growing first-line share can capture a meaningful slice of a potentially $20B+ market, while recent data and patent dynamics support a longer runway for cash flow growth. Beyond Attruby, the company has three NDA submissions and multiple de-risked programs—ribitol, encaleret, and infigratinib—plus $720MM of cash at quarter-end and $1B of preferred equity financing, giving it funding to advance toward profitability.

BridgeBio Pharma is facing a difficult fundamental setup because its late-stage portfolio still carries meaningful clinical, regulatory, and commercial execution risk, and key assets may fail to show enough safety or efficacy for approval. Its lead ATTR-CM drug, Attruby, could struggle against Pfizer’s Vyndaqel/Vyndamax and may not penetrate the market meaningfully, while infigratinib also faces adoption risk, especially in the US. Financially, the company’s limited cash reserves and roughly $1.9B of debt, including $450MM due in 2029, heighten refinancing and solvency concerns if pipeline or launch performance disappoints.